Stocks & Investing
Fri, March 31, 2023
[ Fri, Mar 31st 2023
] - WOPRAI
Fri, February 24, 2023
[ Fri, Feb 24th 2023
] - WOPRAI
Mon, October 31, 2022
[ Mon, Oct 31st 2022
] - WOPRAI
Wed, July 6, 2022
[ Wed, Jul 06th 2022
] - WOPRAI
[ Wed, Jul 06th 2022
] - WOPRAI
[ Wed, Jul 06th 2022
] - WOPRAI
Thu, August 8, 2019
[ Thu, Aug 08th 2019
] - WOPRAI
Wed, May 9, 2018
[ Wed, May 09th 2018
] - WOPRAI
Wed, November 23, 2016
[ Wed, Nov 23rd 2016
] - WOPRAI
Tue, December 22, 2015
William Maughan Maintained (YMAB) at Strong Buy with Decreased Target to $18 on, Mar 31st, 2023
William Maughan of Canaccord Genuity, Maintained "Y-mAbs Therapeutics, Inc." (YMAB) at Strong Buy with Decreased Target from $20 to $18 on, Mar 31st, 2023.
William has made no other calls on YMAB in the last 4 months.
There are 4 other peers that have a rating on YMAB. Out of the 4 peers that are also analyzing YMAB, 2 agree with William's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Joseph Thome of "Cowen & Co." Downgraded from Buy to Hold on, Thursday, January 5th, 2023
- Alec Stranahan of "B of A Securities" Maintained at Hold with Increased Target to $6 on, Thursday, December 15th, 2022
These are the ratings of the 2 analyists that currently disagree with William
- Etzer Darout of "BMO Capital" Maintained at Buy with Increased Target to $13 on, Monday, January 30th, 2023
- Michael Ulz of "Morgan Stanley" Downgraded from Hold to Sell on, Friday, January 27th, 2023
